Tactile Systems Technology came into this Q3 2026 report with a mixed tape. The stock had slipped over the past three months, yet into the print it was up double digits over 30 days. Then the release hit and shares jumped 8.4% to US$24.78 in the first session after the numbers.
The headline is about profit quality more than hype. Revenue reached US$91.9m with lymphedema sales at US$81.8m and gross margin widened to 76.7%. That is what drove the reaction and highlighted the contrast between a cautious setup and a more confident view of the income statement.
Impressed by Tactile Systems Technology’s gross margin but want more options with strong fundamentals and resilient balance sheets in case this rebound fades? Compare it with our list of solid balance sheet and fundamentals stocks (24 results).
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs. Q3 2025): US$91.9m vs. US$85.8m (+7.1%)
- Net Income (Q3 2026 vs. Q3 2025): US$7.2m vs. US$8.2m (declined 12.8%)
- Basic EPS (Q3 2026 vs. Q3 2025): US$0.32 vs. US$0.37 (fell 14.0%)
- Gross Margin (Q3 2026 vs. Q3 2025): 76.7% vs. 75.8% (expanded by 0.9 percentage points)
Earnings paint one picture, but investors who care about what they are really paying for usually focus on the cash coming in and out of the business. Tactile Systems Technology's recent results look stronger on the income statement than they do on pure cash generation, and based on those cash flows alone the stock could be a slight 14% overvalued.
Tactile Systems Technology: Bull Story Meets Early Proof Points
The bullish view hinges on Tactile Systems Technology turning AI tools and new care channels into real operating leverage rather than just a slide deck idea.
"Compounding margin improvement from Tactile Systems Technology’s AI driven workflow, which is already live across order intake, medical record review and Medicare prior authorization, with Q1 and Q2 2026 gross margins in the mid 70s, creates room for further operating leverage as higher volume flows through a leaner back office and supports future EBITDA margin expansion."
Q3 gross margin at 76.7% and adjusted EBITDA of US$14.3m, alongside a raised full year EBITDA outlook but unchanged revenue guide, point to that efficiency story starting to show up in the numbers rather than just in expectations.
Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.
Tactile Systems Technology Bear Case Finds Fresh Fuel
Bears worry that Tactile Systems Technology can widen gross margin yet still see earnings power capped by reimbursement friction and airway softness.
"Despite recent gross margin expansion into the mid 70% range, the introduction of Medicare prior authorization for pneumatic compression devices from April 2026 is adding steps and lengthening order to shipment times. This could suppress lymphedema revenue growth, delay cash collection and limit the conversion of higher margins into stronger net earnings."
Q3 shows part of that concern playing out. Lymphedema growth of 13.1% and a 76.7% gross margin supported higher adjusted EBITDA, yet GAAP net income slipped 12.8%. Airway revenue fell 25.1%, and operating expenses grew faster than sales. Guidance now assumes full year airway contraction, so operating leverage remains uneven.
Hunt Quiet Fundamental Disconnects
Tactile Systems Technology just reminded investors how quickly sentiment can shift when margins move. The real opportunity sits in finding stocks that could be undervalued before the consensus fully aligns with fundamentals.
- Company 1 - 36% below our estimate - scales branded and private label coconut beverages as retailers increase shelf space for a previously niche segment.
- Company 2 - 16% below our estimate - converts engineering wins in regulated hardware into longer contracts that secure complex manufacturing and follow-on support.
- Company 3 - 28% below our estimate - grows fee and interest income by directing more customers into app based services that cross sell credit and savings products.
That is three of the list. See all 35 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com